Targeting homologous recombination-mediated DNA repair in cancer

Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase

(2013) Andrew S. Rosenthal et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

(2013) K. Cramer-Morales et al.   BLOOD

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

(2013) Ruth Thompson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination

(2013) B. Qiao et al.   CANCER RESEARCH

Targeting ATR in DNA damage response and cancer therapeutics

(2013) Emmanouil Fokas et al.   CANCER TREATMENT REVIEWS

A Relationship Between Replication Protein A and Occurrence and Prognosis of Esophageal Carcinoma

(2013) Yu Dahai et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

A Small Molecule Inhibitor of the BLM Helicase Modulates Chromosome Stability in Human Cells

(2013) Giang Huong Nguyen et al.   CHEMISTRY & BIOLOGY

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

(2013) Jiewen Zhu et al.   EMBO Molecular Medicine

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

(2013) Thomas P Matthews et al.   Expert Opinion on Drug Discovery

PARP inhibitors in cancer therapy: an update

(2013) Gianluca Papeo et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Ataxia Telangiectasia-Mutated (ATM) Kinase Activity Is Regulated by ATP-driven Conformational Changes in the Mre11/Rad50/Nbs1 (MRN) Complex

(2013) Ji-Hoon Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Attenuating homologous recombination stimulates an AID-induced antileukemic effect

(2013) Kristin R. Lamont et al.   JOURNAL OF EXPERIMENTAL MEDICINE

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

(2013) A. Min et al.   MOLECULAR CANCER THERAPEUTICS

Caffeine suppresses homologous recombination through interference with RAD51-mediated joint molecule formation

(2013) Alex N. Zelensky et al.   NUCLEIC ACIDS RESEARCH

DIDS (4,4-Diisothiocyanatostilbenedisulphonic Acid) Induces Apoptotic Cell Death in a Hippocampal Neuronal Cell Line and Is Not Neuroprotective against Ischemic Stress

(2013) Matthew E. Pamenter et al.   PLoS One

Human RECQ1 Interacts with Ku70/80 and Modulates DNA End-Joining of Double-Strand Breaks

(2013) Swetha Parvathaneni et al.   PLoS One

Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

(2013) Kyle R. Cron et al.   PLoS One

Ouabain, a Cardiac Glycoside, Inhibits the Fanconi Anemia/BRCA Pathway Activated by DNA Interstrand Cross-Linking Agents

(2013) Dong Wha Jun et al.   PLoS One

Discovery of Protein–Protein Interaction Inhibitors of Replication Protein A

(2013) James D. Patrone et al.   ACS Medicinal Chemistry Letters

Viral Interference with DNA Repair by Targeting of the Single-Stranded DNA Binding Protein RPA

(2013) Pubali Banerjee et al.   PLoS Pathogens

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined “Complementary Lethality”

(2013) Mateusz Rytelewski et al.   Molecular Therapy-Nucleic Acids

Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option

(2012) Ziyan Yuan Pessetto et al.   BREAST CANCER RESEARCH AND TREATMENT

Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

(2012) S. Ying et al.   CANCER RESEARCH

MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition

(2012) Yemin Wang et al.   CANCER RESEARCH

RECQ1 is required for cellular resistance to replication stress and catalyzes strand exchange on stalled replication fork structures

(2012) Venkateswarlu Popuri et al.   CELL CYCLE

MicroRNAs and DNA damage response

(2012) Yemin Wang et al.   CELL CYCLE

Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement

(2012) B. H. Lok et al.   CLINICAL CANCER RESEARCH

The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment

(2012) M. Stiborova et al.   CURRENT MEDICINAL CHEMISTRY

RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma

(2012) Pierre Tennstedt et al.   INTERNATIONAL JOURNAL OF CANCER

Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies

(2012) Berina Eppink et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells

(2012) Pavithra Raghavan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells

(2012) Li-Qing Du et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

An Optimized RAD51 Inhibitor That Disrupts Homologous Recombination without Requiring Michael Acceptor Reactivity

(2012) Brian Budke et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of Homologous Recombination in Human Cells by Targeting RAD51 Recombinase

(2012) Fei Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of MRE11 in Cell Proliferation, Tumor Invasion, and DNA Repair in Breast Cancer

(2012) Shyng-Shiou F. Yuan et al.   JNCI-Journal of the National Cancer Institute

RAD51 Mutants Cause Replication Defects and Chromosomal Instability

(2012) T. M. Kim et al.   MOLECULAR AND CELLULAR BIOLOGY

Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma

(2012) X. Chen et al.   MOLECULAR CANCER RESEARCH

Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase

(2012) Ketki Karanam et al.   MOLECULAR CELL

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells

(2012) Brian Budke et al.   NUCLEIC ACIDS RESEARCH

RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination

(2012) B H Lok et al.   ONCOGENE

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

(2012) S. R. Stecklein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells

(2012) Jen-Chung Ko et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening

(2011) Fei Huang et al.   ACS Chemical Biology

A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A

(2011) Elaine M. Souza-Fagundes et al.   ANALYTICAL BIOCHEMISTRY

Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics

(2011) Zhengguan Yang et al.   BIOCHEMICAL PHARMACOLOGY

Functions of the Snf2/Swi2 family Rad54 motor protein in homologous recombination

(2011) Shannon J. Ceballos et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods

(2011) Jason G. Glanzer et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

PARP inhibitors – current status and the walk towards early breast cancer

(2011) Jennifer Glendenning et al.   BREAST

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells

(2011) Johanne I Weberpals et al.   Cancer Cell International

RECQL1 and WRN Proteins Are Potential Therapeutic Targets in Head and Neck Squamous Cell Carcinoma

(2011) A. Arai et al.   CANCER RESEARCH

Defective homologous recombination in human cancers

(2011) A. Cerbinskaite et al.   CANCER TREATMENT REVIEWS

Mre11–Rad50 complex crystals suggest molecular calisthenics

(2011) Claire Wyman et al.   DNA REPAIR

Small-molecule inhibitors of the PI3K signaling network

(2011) Colleen R McNamara et al.   Future Medicinal Chemistry

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

(2011) E Kiyohara et al.   GENE THERAPY

Developing therapeutic microRNAs for cancer

(2011) A G Bader et al.   GENE THERAPY

BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair

(2011) A. V. Nimonkar et al.   GENES & DEVELOPMENT

Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51

(2011) Motoki Takaku et al.   GENES TO CELLS

Replication protein A: a reliable biologic marker of prognostic and therapeutic value in human astrocytic tumors

(2011) Dimitrios Kanakis et al.   HUMAN PATHOLOGY

Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity

(2011) Zacharoula Konsoula et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

ATP-dependent and independent functions of Rad54 in genome maintenance

(2011) Sheba Agarwal et al.   JOURNAL OF CELL BIOLOGY

Structure–Activity Relationship Studies To Probe the Phosphoprotein Binding Site on the Carboxy Terminal Domains of the Breast Cancer Susceptibility Gene 1

(2011) Ziyan Yuan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of Interaction of XPF with RPA in Nucleotide Excision Repair

(2011) Laura A. Fisher et al.   JOURNAL OF MOLECULAR BIOLOGY

Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma

(2011) Yong Li et al.   JOURNAL OF SURGICAL ONCOLOGY

The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation

(2011) Ramiro Mendoza-Maldonado et al.   Molecular Cancer

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin

(2011) T. M. Neher et al.   MOLECULAR CANCER THERAPEUTICS

Rad51 Promoter-Targeted Gene Therapy Is Effective for In Vivo Visualization and Treatment of Cancer

(2011) Christopher M Hine et al.   MOLECULAR THERAPY

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155

(2011) Suhwan Chang et al.   NATURE MEDICINE

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

The MRE11 complex: starting from the ends

(2011) Travis H. Stracker et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Unraveling the mechanism of BRCA2 in homologous recombination

(2011) William K Holloman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Berberine Radiosensitizes Human Esophageal Cancer Cells by Downregulating Homologous Recombination Repair Protein RAD51

(2011) Qiao Liu et al.   PLoS One

Adenoviral Vector Driven by a Minimal Rad51 Promoter Is Selective for p53-Deficient Tumor Cells

(2011) Vincent Fong et al.   PLoS One

Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress

(2011) M. Aggarwal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

(2011) P. M. Krawczyk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination

(2011) Helen Zhao et al.   RADIOTHERAPY AND ONCOLOGY

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Exploiting the P-1 Pocket of BRCT Domains Toward a Structure Guided Inhibitor Design

(2011) Ziyan Yuan et al.   ACS Medicinal Chemistry Letters

The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination

(2011) Yong Qing et al.   PLoS Genetics

The RecQ DNA Helicases in DNA Repair

(2010) Kara A. Bernstein et al.   Annual Review of Genetics

Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination

(2010) Susan F. Martinez et al.   BIOCHIMIE

Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma

(2010) Georgia Levidou et al.   BJU INTERNATIONAL

Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer

(2010) K Araki et al.   BRITISH JOURNAL OF CANCER

Telomerase-Dependent Oncolytic Adenovirus Sensitizes Human Cancer Cells to Ionizing Radiation via Inhibition of DNA Repair Machinery

(2010) S. Kuroda et al.   CANCER RESEARCH

The Human WRN and BLM RecQ Helicases Differentially Regulate Cell Proliferation and Survival after Chemotherapeutic DNA Damage

(2010) F. J. Mao et al.   CANCER RESEARCH

Targeted Inhibition of Replication Protein A Reveals Cytotoxic Activity, Synergy with Chemotherapeutic DNA-Damaging Agents, and Insight into Cellular Function

(2010) S. C. Shuck et al.   CANCER RESEARCH

Secondary mutations of BRCA1/2 and drug resistance

(2010) Kiranjit K. Dhillon et al.   CANCER SCIENCE

Making the best of the loose ends: Mre11/Rad50 complexes and Sae2 promote DNA double-strand break resection

(2010) Tanya T. Paull   DNA REPAIR

High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome

(2010) Raffaela Barbano et al.   INTERNATIONAL JOURNAL OF CANCER

Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition

(2010) Claudia Blattmann et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Design of Potent Inhibitors of Human RAD51 Recombinase Based on BRC Motifs of BRCA2 Protein: Modeling and Experimental Validation of a Chimera Peptide

(2010) Julian Nomme et al.   JOURNAL OF MEDICINAL CHEMISTRY

Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non-Small-Cell Lung Cancer Cells

(2010) M.-S. Tsai et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Knockdown of Rad51 expression induces radiation- and chemo-sensitivity in osteosarcoma cells

(2010) Li-Qing Du et al.   MEDICAL ONCOLOGY

miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors

(2010) Patryk Moskwa et al.   MOLECULAR CELL

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

(2010) Alfons Meindl et al.   NATURE GENETICS

Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor

(2010) Sushant K. Kachhap et al.   PLoS One

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rad52 inactivation is synthetically lethal with BRCA2 deficiency

(2010) Z. Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Physical Interaction between Replication Protein A (RPA) and MRN: Involvement of RPA2 Phosphorylation and the N-Terminus of RPA1

(2009) Greg G. Oakley et al.   BIOCHEMISTRY

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

(2009) Wenqing Qi et al.   BMC CANCER

The vital link between the ubiquitin–proteasome pathway and DNA repair: Impact on cancer therapy

(2009) Akira Motegi et al.   CANCER LETTERS

Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

(2009) D. N. Yarde et al.   CANCER RESEARCH

PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response

(2009) Feng Zhang et al.   CURRENT BIOLOGY

Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation

(2009) Ruey-Shyang Chen et al.   EXPERIMENTAL CELL RESEARCH

Overexpression of RAD51 occurs in aggressive prostatic cancer

(2009) Anita Mitra et al.   HISTOPATHOLOGY

Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme

(2009) James W. Welsh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Hitting the bull's eye: Novel directed cancer therapy through helicase-targeted synthetic lethality

(2009) Monika Aggarwal et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

(2009) Waleed M. Abuzeid et al.   JOURNAL OF CLINICAL INVESTIGATION

Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase-AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non-Small Cell Lung Cancer Cells

(2009) J.-C. Ko et al.   MOLECULAR CANCER RESEARCH

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

(2009) F. A. Dungey et al.   MOLECULAR CANCER THERAPEUTICS

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

(2009) A. Choudhury et al.   MOLECULAR CANCER THERAPEUTICS

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

(2009) Neil Johnson et al.   MOLECULAR CELL

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

(2009) John Nemunaitis et al.   MOLECULAR THERAPY

Corrected structure of mirin, a small-molecule inhibitor of the Mre11–Rad50–Nbs1 complex

(2009) Kristen M Garner et al.   Nature Chemical Biology

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange

(2009) Takako Ishida et al.   NUCLEIC ACIDS RESEARCH

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

(2009) James W Welsh et al.   Radiation Oncology

Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo

(2008) Dong Yu et al.   CANCER SCIENCE

The consequences of Rad51 overexpression for normal and tumor cells

(2008) Hannah L. Klein   DNA REPAIR

Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein

(2008) Julian Nomme et al.   GENES TO CELLS

Hereditary breast cancer: new genetic developments, new therapeutic avenues

(2008) Philippe M. Campeau et al.   HUMAN GENETICS

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

(2008) Johanne Weberpals et al.   INTERNATIONAL JOURNAL OF CANCER

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

(2008) Kyunghee Burkitt et al.   Molecular Cancer

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells

(2008) J.-C. Ko et al.   MOLECULAR CANCER THERAPEUTICS

A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex

(2008) Aude Dupré et al.   Nature Chemical Biology

Use of the Rad51 promoter for targeted anti-cancer therapy

(2008) C. M. Hine et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT–phosphoprotein interaction

(2007) Anton Simeonov et al.   ANALYTICAL BIOCHEMISTRY